English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/153671
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Synthesis and biological assessment of racemic benzochromenopyrimidinetriones as promising agents for Alzheimer's disease therapy

AuthorsDgachi, Youssef; Martin, Hélène; Bonet, Alexandre; Chioua, Mourad ; Iriepa, Isabel; Moraleda, Ignacio; Chabchoub, Fakher; Marco-Contelles, José ; Ismaili, Lhassane
KeywordsTacrine analogs
Cholinesterase inhibitors
Cholinesterase enzymes
Alzheimer’s disease
Issue Date2017
PublisherFuture Science
CitationFuture Medicinal Chemistry 9: 715-721 (2017)
AbstractAim: Due to the complex nature of Alzheimer's disease, there is a renewed search for multitarget directed drugs. Results: This paper describes the synthesis and in vitro biological evaluation of six racemic 13-aryl-2,3,4,13-tetrahydro-1H,12H-benzo[6,7]chromeno[2,3-d]pyrido[1,2-a]pyrimidine-7,12,14-triones (1a-6a), and six racemic 15-aryl-8,9,10,11,12,15-hexahydro-14H-benzo[6′,7′]chromeno[2′,3:4,5] pyr-imido [1,2-a]azepine-5,14,16-triones (1b-6b), showing antioxidant and cholinesterase inhibitory capacity. Among these compounds, 13-phenyl-2,3,4,13-tetrahydro-1H,12H-benzo[6,7]chromeno[2,3-d]pyrido[1,2-a]pyrimidine-7,12,14-trione (1a) is a nonhepatotoxic at 300 μmol/l dose concentration, and a selective EeAChE inhibitor showing good antioxidant power. Conclusion: A new family of racemic benzochromenopyrimidinetriones has been investigated for their potential use in the treatment of Alzheimer's disease.
Identifiersdoi: 10.4155/fmc-2017-0004
issn: 1756-8919
e-issn: 1756-8927
Appears in Collections:(IQOG) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.